Pharmacological modulation of human mast cells and basophils

Clinical and Experimental Allergy

Volumn 32, Issue 12, 2002, Pages 1682-1689

  Marone, Gianni ^a   Genovese, A ^a   Granata, F ^a   Forte, V ^a   Detoraki, A ^a   De Paulis, A ^a   Triggiani, M ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 6 [4 (1,4 DIHYDRO 4 OXO 1 PYRIDYL)PHENYL] 4,5 DIHYDRO 5 METHYL 3(2H) PYRIDAZINONE; ACETYLSALICYLIC ACID; ADENYLATE CYCLASE ACTIVATOR; ANTIINFLAMMATORY AGENT; CATECHOLAMINE DERIVATIVE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DEFLAZACORT; DEXAMETHASONE; DICLOFENAC; FENOTEROL; FORMOTEROL; GLUCOCORTICOID; HISTAMINE; HYDROCORTISONE; IMMUNOPHILIN; INDOMETACIN; ISOPRENALINE; MECLOFENAMIC ACID; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PIROXICAM; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SALMETEROL; SIGUAZODAN; TACROLIMUS; UNINDEXED DRUG; ZAPRINAST; ENZYME INHIBITOR; HISTAMINE H1 RECEPTOR ANTAGONIST; PROTEIN KINASE C; PROTEIN TYROSINE KINASE;

ARTHRITIS; ATOPIC DERMATITIS; BASOPHIL; BASOPHIL DEGRANULATION; CELL DENSITY; COMPLEX FORMATION; CONCENTRATION RESPONSE; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; HISTAMINE RELEASE; HUMAN; IMMUNOMODULATION; INFLAMMATION; LUNG ALVEOLUS CELL; MAST CELL; MEDIATOR RELEASE; OINTMENT; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN CELL; SYNOVIOCYTE; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METABOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BASOPHILS; ENZYME INHIBITORS; GLUCOCORTICOIDS; HISTAMINE H1 ANTAGONISTS; HUMANS; IMMUNOPHILINS; MAST CELLS; PHOSPHODIESTERASE INHIBITORS; PROTEIN KINASE C; PROTEIN-TYROSINE KINASES;

EID: 0036456991     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2002.01535.x     Document Type: Review

References (98)

1. Marone G, Lichtenstein LM, Galli SJ. Mast Cells and Basophils. San Diego: Academic Press, 2000.
2. Dvorak AM, Galli SJ, Schulman ES, Lichtenstein LM, Dvorak HF. Basophil and mast cell degranulation: Ultrastructural analysis of mechanisms of mediator release. Fed Proc 1983; 42:2510-5.
3. Casolaro V, Galeone D, Giacummo A, Sanduzzi A, Melillo G, Marone G. Human basophil/mast cell releasability. V. Functional comparisons of cells obtained from peripheral blood, lung parenchyma, and bronchoalveolar lavage in asthmatics. Am Rev Respir Dis 1989; 139:1375-82.
4. Dvorak AM. Ultrastructural analysis of human mast cells and basophils. In: Marone G, ed. Human Basophils and Mast Cells: Biological Aspects. Basel: Karger, 1995; 1-33.
5. Triggiani M, Oriente A, Seeds MC, Bass DA, Marone G, Chilton FH. Migration of human inflammatory cells into the lung results in the remodeling of arachidonic acid into a triglyceride pool. J Exp Med 1995; 182:1181-90.
6. Nilsson G, Miettinen U, Ishizaka T, Ashman LK, Irani AM, Schwartz LB. Interleukin-4 inhibits the expression of Kit and tryptase during stem cell factor-dependent development of human mast cells from fetal liver cells. Blood 1994; 84:1519-27.
7. Naclerio RM, Proud D, Togias AG et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985; 313:65-70.
8. Charlesworth EN, Hood AF, Soter NA, Kagey-Sobotka A, Norman PS, Lichtenstein LM. Cutaneous late-phase response to allergen. Mediator release and inflammatory cell infiltration. J Clin Invest 1989; 83:1519-26.
9. Iliopoulos O, Baroody FM, Naclerio RM, Bochner BS, Kagey-Sobotka A, Lichtenstein LM. Histamine-containing cells obtained from the nose hours after antigen challenge have functional and phenotypic characteristics of basophils. J Immunol 1992; 148:2223-8.
10. Liu MC, Hubbard WC, Proud D et al. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir Dis 1991; 144:51-8.
11. Bradding P, Feather IH, Howarth PH. Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992; 176:1381-6.
12. MacGlashan D Jr, White JM, Huang SK, Ono SJ, Schroeder JT, Lichtenstein LM. Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol 1994; 152:3006-16.
13. Li H, Sim TC, Alam R. IL-13 released by and localized in human basophils. J Immunol 1996; 156:4833-8.
14. Ohkawara Y, Yamauchi K, Tanno Y et al. Human lung mast cells and pulmonary macrophages produce tumor necrosis factor-alpha in sensitized lung tissue after IgE receptor triggering. Am J Respir Cell Mol Biol 1992; 7:385-92.
15. Bradding P, Roberts JA, Britten KM et al. Interleukin-4, -5 and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: Evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10:471-80.
16. Burd PR, Thompson WC, Max EE, Mills FC. Activated mast cells produce interleukin 13. J Exp Med 1995; 181:1373-80.
17. Kruger-Krasagakes S, Moller A, Kolde G, Lippert U, Weber M, Henz BM. Production of interleukin-6 by human mast cells and basophilic cells. J Invest Dermatol 1996; 106:75-9.
18. Marone G, Casolaro V, Patella V, Florio G, Triggiani M. Molecular and cellular biology of mast cells and basophils. Int Arch Allergy Immunol 1997; 114:207-17.
19. + T lymphocyte chemoattractant factor, IL-16. J Immunol 1997; 159:2904-10.
20. Patella V, Marino I, Arbustini E et al. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation 1998; 97:971-8.
21. Brunner T, Heusser CH, Dahinden CA. Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. J Exp Med 1993; 77:605-11.
22. Li H, Sim TC, Grant JA, Alam R. The production of macrophage inflammatory protein- 1 alpha by human basophils. J Immunol 1996; 157:1207-12.
23. Gauchat JF, Henchoz S, Mazzei Get al. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 1993; 365:340-3.
24. + cells. J Immunol 1991; 146:2374-81.
25. de Paulis A, Ciccarelli A, de Crescenzo G, Cirillo R, Patella V, Marone G. Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by N-formyl-methionyl-leucyl-phenylalanine. J Allergy Clin Immunol 1996; 98:152-64.
26. de Paulis A, Ciccarelli A, Marino I, de Crescenzo G, Marino D, Marone G. Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs. Arthritis Rheum 1997; 40:469-78.
27. Marone G. Immunosuppressive treatment of chronic asthma. In: Lichtenstein LM, Fauci AS, eds. Current Therapy in Allergy, Immunology, and Rheumatology. Toronto: B.C. Decker, 1992:368-71.
28. Casolaro V, Spadaro G, Patella V, Marone G. In vivo characterization of the anti-inflammatory effect of cyclosporin A on human basophils. J Immunol 1993; 151:5563-73.
29. Weston MC, Peachell PT. Regulation of human mast cell and basophil function by cAMP. General Pharmacol 1998; 31:715-9.
30. Reischl IG, Coward WR, Church MK. Molecular consequences of human mast cell activation following immunoglobulin E-high-affinity immunoglobulin E receptor (IgE-FcεRI) interaction. Biochem Pharmacol 1999; 58:1841-50.
31. Oliver JM, Kepley CL, Ortega E, Wilson BS. Immunologically mediated signaling in basophils and mast cells: Finding therapeutic targets for allergic diseases in the human FcεRI signaling pathway. Immunopharmacology 2000; 48:269-81.
32. Bastan R, Peirce M J, Peachell PT. Regulation of immunoglobulin E-mediated secretion by protein phosphatases in human basophils and mast cells of skin and lung. Eur J Pharmacol 2001; 430:135-41.
33. Lichtenstein LM, Margolis S. Histamine release in vitro: Inhibition by catecholamines and methylxanthines. Science 1968; 161:902-3.
34. Giembycz MA. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here? Drugs 2000; 59:193-212.
35. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001; 108:671-80.
36. Muller T, Engels P, Fozard JR. Subtypes of the type 4 cAMP phosphodiesterases: Structure, regulation and selective inhibition. Trends Pharmacol Sci 1996; 17:294-8.
37. Columbo M, Horowitz EM, McKenzie-White J, Kagey-Sobotka A, Lichtenstein LM. Pharmacologic control of histamine release from human basophils induced by platelet-activating factor. Int Arch Allergy Immunol 1993; 102:383-90.
38. Peachell PT, Undem BJ, Schleimer RP et al. Preliminary identification and role of phosphodiesterase isozymes in human basophils. J Immunol 1992; 148:2503-10.
39. Marone G, Columbo M, Triggiani M, Cirillo R, Genovese A, Formisano S. Inhibition of IgE-mediated release of histamine and peptide leukotriene from human basophils and mast cells by forskolin. Biochem Pharmacol 1987; 36:13-20.
40. Torphy TJ, Livi GP, Balcarek JM, White JR, Chilton FH, Undem BJ. Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma. Adv Second Messenger Phosphoprotein Res 1992; 25:289-305.
41. Balibrea-Cantero JL, Arias-Diaz J, Garcia C et al. Effect of pentoxifylline on the inhibition of surfactant synthesis induced by TNF-alpha in human type II pneumocytes. Am J Respir Crit Care Med 1994; 149:699-706.
42. Marone G, Spadaro G, De Marino V, Aliperta M, Triggiani M. Immunopharmacology of human mast cells and basophils. Int J Clin Laboratory Res 1998; 28:12-22.
43. Marone G, Ambrosio G, Bonaduce D, Genovese A, Triggiani M, Condorelli M. Inhibition of IgE-mediated histamine release from human basophils and mast cells by fenoterol. Int Arch Allergy Appl Immunol 1984; 74:356-61.
44. Crane J, Pearce N, Flatt A et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: Case-control study. Lancet 1989; 1:917-22.
45. Nials AT, Ball DI, Butchers PR et al. Formoterol on airway smooth muscle and human lung mast cells: A comparison with salbutamol and salmeterol. Eur J Pharmacol 1994; 251:127-35.
46. 2 (s); comparison of arachidonoyl-selective and-nonselective enzymes. Faseb J 1993; 7:33948.
47. Hamasaki Y, Kitzler J, Hardman R, Nettesheim P, Eling TE. Phorbol ester and epidermal growth factor enhance the expression of two inducible prostaglandin H synthase genes in rat tracheal epithelial cells. Arch Biochem Biophys 1993; 304:226-34.
48. Marone G, Kagey-Sobotka A, Lichtenstein LM. Effects of arachidonic acid and its metabolites on antigen-induced histamine release from human basophils in vitro. J Immunol 1979; 123:1669-77.
49. Marone G, Kagey-Sobotka A, Lichtenstein LM. IgE-mediated histamine release from human basophils: Differences between antigen E- and anti-IgE-induced secretion. Int Arch Allergy Appl Immunol 1981; 65:339-48.
50. Marone G, Columbo M, Cirillo R, Condorelli M. Studies on the pathophysiology of aspirin idiosyncrasy. In: Bonomo L, Tursi A, eds. Recent Advances in Allergology. Florence: O.I.C. Medical Press, 1986; 77-97.
51. Wojnar R J, Hearn T, Starkweather S. Augmentation of allergic histamine release from human leukocytes by nonsteroidal antiinflammatory-analgesic agents. J Allergy Clin Immunol 1980; 66:37-45.
52. Swingle KF, Moore GG, Grant TJ. 4-nitro-2-phenoxymethanesulfonanilide (R-805): A chemically novel anti-inflammatory agent. Arch Int Pharmacodyn Ther 1976; 221:132-9.
53. + cells by nimesulide. Agents Actions 1992; 32:C311-C4.
54. Casolaro V, Meliota S, Marino O et al. Nimesulide, a sulfonanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells. J Pharmacol Exp Ther 1993; 267:1375-85.
55. Andri L, Senna G, Betteli C, Givanni S, Scaricabarozzi I, Mezzelani P, Andri G. Tolerability of nimesulide in aspirin-sensitive patients. Ann Allergy 1994; 72:29-32.
56. Patella V, de Crescenzo G, Marino I et al. Eosinophil granule proteins activate human heart mast cells. J Immunol 1996; 157:1219-25.
57. Ward A, Brogden RN. Nimesulide. A preliminary review of its pharmacological properties and therapeutic efficacy in inflammation and pain states. Drugs 1988; 36:732-53.
58. Bakhle YS, Botting RM. Cyclooxygenase-2 and its regulation in inflammation. Med Inflammation 1996; 5:305-23.
59. Spangler RS. Cyclooxygenase 1 and 2 in rheumatic disease: Implications for nonsteroidal anti-inflammatory drug therapy. Semin Arthritis Rheum 1996; 26:435-46.
60. Schleimer RP, Hamid Q. Regulation of allergic airways inflammation by cytokines and glucocorticoids. In: Marone G, Austen KF, Holgate ST, Kay AB, Lichtenstein LM, eds. Asthma and Allergic Diseases. Physiology. Immunopharmacology and Treatment. London: Academic Press, 1998; 337-55.
61. Dunsky EH, Zweiman B, Fischler E, Levy DA. Early effects of corticosteroids on basophils, leukocyte histamine, and tissue histamine. J Allergy Clin Immunol 1979; 63:426-32.
62. Lavker RM, Schechter NM. Cutaneous mast cell depletion results from topical corticosteroid usage. J Immunol 1985; 135:2368-73.
63. Schleimer RP, Lichtenstein LM, Gillespie E. Inhibition of basophil histamine release by anti-inflammatory steroids. Nature 1981; 292:454-5.
64. Stellato C, de Paulis A, Ciccarelli A et al. Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol 1992; 98:800-4.
65. Schleimer RP, Schulman ES, MacGlashan DW et al. Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest 1983; 71:1830-5.
66. Schroeder JT, MacGlashan DW Jr, MacDonald SM, Kagey-Sobotka A, Lichtenstein LM. Regulation of IgE-dependent IL-4 generation by human basophils treated with glucocorticoids. J Immunol 1997; 158:5448-54.
67. Chang EY, Szallasi Z, Acs P et al. Functional effects of overexpression of protein kinase C-α, -β, -δ, -ε, and -η in the mast cell line R13L-2H3. J Immunol 1997; 159:2624-32.
68. Schleimer RP, Gillespie E, Lichtenstein LM. Release of histamine from human leukocytes stimulated with the tumor-promoting phorbol diesters. I. Characterization of the response. J Immunol 1981; 126:570-4.
69. Patella V, Casolaro V, Ciccarelli A, Pettit GR, Columbo M, Marone G. The antineoplastic bryostatins affect human basophils and mast cells differently. Blood 1995; 85:1272-81.
70. Warner JA, MacGlashan DW Jr. Signal transduction events in human basophils. A comparative study of the role of protein kinase C in basophils activated by anti-IgE antibody and formyl-methionyl-leucyl-phenylalanine. J Immunol 1990; 145:1897-905.
71. Massey WA, Cohan VL, MacGlashan DW Jr et al. Protein kinase C modulates immunoglobulin E-mediated activation of human mast cells from lung and skin. I. Pharmacologic inhibition. J Pharmacol Exp Ther 1991; 258:824-9.
72. Miura K, MacGlashan DW Jr. Expression of protein kinase C isozymes in human basophils: Regulation by physiological and nonphysiological stimuli. Blood 1998; 92:1206-18.
73. Bergstrand H, Lundquist B, Karabelas K, Michelsen P. Modulation of human basophil histamine release by protein kinase C inhibitors differs with secretagogue and with inhibitor. J Pharmacol Exp Ther 1992; 260:1028-37.
74. Miura K, MacGlashan DW. Phosphatidylinositol-3 kinase regulates p21ras activation during IgE-mediated stimulation of human basophils. Blood 2000; 96:2199-205.
75. Coussens L, Parker P J, Rhee L et al. Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. Science 1986; 233:859-66.
76. Benhamou M, Gutkind JS, Robbins KC, Siraganian RP. Tyrosine phosphorylation coupled to IgE receptor-mediated signal transduction and histamine release. Proc Natl Acad Sci USA 1990; 87:5327-30.
77. Kepley CL, Wilson BS, Oliver JM. Identification of the Fc epsilonRI-activated tyrosine kinases Lyn, Syk, and Zap-70 in human basophils. J Allergy Clin Immunol 1998; 102:304-15.
78. Lavens SE, Peachell PT, Warner JA. Role oftyrosine kinases in IgE-mediated signal transduction in human lung mast cells and basophils. Am J Respir Cell Mol Biol 1992; 7:637-44.
79. Miura K, Lavens-Phillips S, MacGlashan DW Jr. Piceatannol is an effective inhibitor of IgE-mediated secretion from human basophils but is neither selective for this receptor nor acts on syk kinase at concentrations where mediator release inhibition occurs. Clin Exp Allergy 2001; 31:1732-9.
80. Hait WN, Harding MW, Handschumacher RE. Calmodulin, cyclophilin, cyclosporin A. Sci 1986; 233:987-9.
81. Standaert RF, Galat A, Verdine GL, Schreiber SL. Molecular cloning and overexpression of the human FK506-binding protein FKBP. Nature 1990; 346:671-4.
82. O'Keefe S J, Tamura J, Kincaid RL, Tocci M J, O'Neill EA. FK-506-and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992; 357:692-4.
83. Cirillo R, Triggiani M, Siri L et al. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol 1990; 144:3891-7.
84. de Paulis A, Stellato C, Cirillo R, Ciccarelli A, Oriente A, Marone G. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 1992; 99:723-8.
85. Kuo C J, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin selectively inhibits interleukin-2 activation of p70, S6 kinase. Nature 1992; 358:70-3.
86. H3 region of IgE. J Immunol 1998; 161:5647-55.
87. Florio G, Petraroli A, Patella V, Triggiani M, Marone G. The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophils. AIDS 2000; 14:931-8.
88. Ruzicka T, Bieber T, Schopf E et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337:816-21.
89. Mitchell EB, Crow J, Chapman MD, Jouhal SS, Pope FM, Platts-Mills TA. Basophils in allergen-induced patch test sites in atopic dermatitis. Lancet 1982; 1:127-30.
90. Marone G. Tacrolimus ointment for atopic dermatitis. N Engl J Med 1998; 339:1788-9.
91. Marone G. Milestones in the biology and pharmacology of H1-receptor antagonists. Allergy 1997; 52:7-13.
92. Lichtenstein LM, Gillespie E. The effects of the H1 and H2 antihistamines on allergic histamine release and its inhibition by histamine. J Pharmacol Exp Ther 1975; 192:441-50.
93. Church MK, Gradidge CF. Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. Br J Pharmacol 1980; 69:663-7.
94. Patella V, de Crescenzo G, Marino O, Spadaro G, Genovese A, Marone G. Oxatomide inhibits the release of proinflammatory mediators from human basophils and mast cells. Int Arch Allergy Immunol 1996; 111:23-9.
95. + cells. Clin Exp Allergy 1997; 27:559-67.
96. Church MK. Non-H1-receptor effects of antihistamines. Clin Exp Allergy 1999; 29 (Suppl. 3):39-48.
97. Marone G, Granata F, Spadaro G, Onorati AM, Triggiani M. Antiinflammatory effects of oxatomide. J Invest Allergol Clin Immunol 1999; 9:207-14.
98. Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001; 31:1369-77.